Sungjoon Cho
Overview
Explore the profile of Sungjoon Cho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho S, Won C, Kwon C, Kim H, Lee S, Yoon K, et al.
ACS Sens
. 2025 Jan;
10(1):148-158.
PMID: 39801273
Bioelectronic face masks can easily collect biomarkers in saliva, in which free cortisol is abundant. However, conventional bioelectronic face masks involve significant challenges in terms of permeability and inhalation due...
2.
Kim J, Won C, Ham S, Han H, Shin S, Jang J, et al.
Biomedicines
. 2024 Oct;
12(10).
PMID: 39457482
Background: Keloids are a common fibrotic disease of the skin, with the pathological hallmark of excessive extracellular matrix synthesis due to abnormal fibroblast activity. Since keloids clinically arise in areas...
3.
Cho S, Shin S, Lee S, Rhee Y, Kim H, Hong N
Endocrinol Metab (Seoul)
. 2024 Jul;
39(4):632-640.
PMID: 39015029
Backgruound: Osteoporosis and fragility fractures are crucial musculoskeletal complications in long-term survivors of gastric cancer. However, the relationship between changes in body composition after gastrectomy and bone loss has not...
4.
Cho S, Cheruzel L, Cai J, Wrigley S, Gemmell R, Kokubun T, et al.
Drug Metab Dispos
. 2024 Jul;
52(9):981-987.
PMID: 38991780
Two unique metabolites (M18 and M19) were detected in feces of human volunteers dosed orally with [C]inavolisib with a molecular ion of parent plus 304 Da. They were generated in...
5.
Khojasteh S, Argikar U, Chatzopoulou M, Cheruzel L, Cho S, Dhaware D, et al.
Drug Metab Rev
. 2024 Jul;
56(3):190-222.
PMID: 38989688
This annual review marks the eighth in the series starting with Baillie et al. (2016) Our objective is to explore and share articles which we deem influential and significant in...
6.
Wang S, Argikar U, Chatzopoulou M, Cho S, Crouch R, Dhaware D, et al.
Drug Metab Rev
. 2024 Jul;
56(3):247-284.
PMID: 38963129
Advances in the field of bioactivation have significantly contributed to our understanding and prediction of drug-induced liver injury (DILI). It has been established that many adverse drug reactions, including DILI,...
7.
Ma B, Argikar U, Cheruzel L, Cho S, Hauri S, Johnson K, et al.
Drug Metab Rev
. 2024 Jun;
56(3):223-246.
PMID: 38895934
With contributions from colleagues across academia and industry, we have put together the annual reviews of research advances on drug biotransformation and bioactivation since 2016 led by Cyrus Khojasteh. While...
8.
Kim K, Baek S, Yu M, Shin S, Cho S, Rhee Y, et al.
JBMR Plus
. 2024 Jun;
8(7):ziae065.
PMID: 38868595
Data on epidemiology and secular trend in primary hyperparathyroidism (PHPT) in adults are relatively limited in Asian countries. This study aims to provide an overview of the secular trends in...
9.
Kshirsagar S, Chen Y, Yu J, Gates M, Kawakatsu S, Khojasteh S, et al.
Drug Metab Dispos
. 2024 Jun;
52(8):847-857.
PMID: 38834357
Giredestrant is a potent and selective small-molecule estrogen receptor degrader. The objectives of this study were to assess the absolute bioavailability (aBA) of giredestrant and to determine the mass balance,...
10.
Khojasteh S, Argikar U, Cheruzel L, Cho S, Crouch R, Dhaware D, et al.
Drug Metab Rev
. 2023 Sep;
55(4):301-342.
PMID: 37737116
This annual review is the eighth of its kind since 2016 (Baillie et al. 2016, Khojasteh et al. 2017, Khojasteh et al. 2018, Khojasteh et al. 2019, Khojasteh et al....